Jaundice in the newborn period can be physiologic and is often due to benign causes. Jaundice due to conjugated hyperbilirubinemia extending beyond the second week of life may be an early sign of several cholestatic or metabolic liver diseases, and it requires logical and timely analysis so that specific treatments can be initiated. Alpha-1 antitrypsin deficiency is the most common genetic cause of pediatric liver disease and transplantation, and it must be considered when evaluating cholestatic infants. Here, we present an unusual case of alpha-1 antitrypsin deficiency with severe infantile cholestasis and rapid decompensation in the first 4 months of life, where in-depth but timely diagnosis was crucial for the appropriate intervention to take place.
Introduction
Direct hyperbilirubinemia reflects impaired bile flow, and it may be an early sign of idiopathic neonatal hepatitis, biliary atresia, alpha-1 antitrypsin deficiency (A1ATD), Alagille syndrome, tyrosinemia, disorders of energy metabolism, or bile acid synthetic defects. Cholestasis affects 1 in 2500 infants, and it requires logical and timely analysis so that specific treatments can be initiated. Infants with biliary atresia, the most common cause of pediatric liver transplantation, have better outcomes if Kasai hepatic portoenterostomy is performed before 45-60 days of life. 1 Other, less straight-forward diagnoses can potentially be delayed in a well-appearing infant. A classic example of such clinical variability is A1ATD, the most common inherited cause of liver disease in children. In A1ATD, most cases of neonatal cholestasis gradually recover. We report an unusual case of infantile A1ATD, with severe persistent cholestasis and rapid deterioration in the first 4 months of life, requiring early liver transplantation.
Case Presentation
The patient is a term 2807 g infant girl born via uncomplicated spontaneous vaginal delivery. There was no history of neonatal jaundice. Newborn screen was normal. Family history was unremarkable. At $DOL (day of life) 42, the family observed intermittent yellowing of her skin, with pigmented stools. At DOL 109, her pediatrician noted jaundice. She was referred to our center for urgent evaluation.
On exam, she was alert and afebrile, but icteric, with hepatosplenomegaly, prominent abdominal vessels, and no appreciable ascites. There were no obvious dysmorphic features. Several acholic stools were observed. Ultrasound showed a normal gallbladder without ductal dilatation, heterogeneous liver echotexture, and normal Doppler flow. Labs during this admission showed normal electrolytes, glucose, thyroid studies, lactate, pyruvate, and uric acid. Infectious work-up was negative. She had a right posterior embryotoxon on fundoscopic exam, raising the question of Alagille syndrome. Spine films showed no vertebral anomalies. Echocardiogram was normal.
Hepatobiliary iminodiacetic acid scan on DOL 115 showed no excretion in the intestine at 24 h, concerning for biliary atresia. She soon developed significant abdominal distention and intermittent hypoglycemia. Repeat labs were unchanged. The patient was readmitted for intraoperative cholangiogram and liver biopsy on DOL 116. A hard nodular liver was noted with normal flow into tiny bile ducts, favoring Alagille syndrome over biliary atresia. A large volume of dark yellow ascites fluid was drained. This appeared transudative, but due to leukocytosis, antibiotics were started for presumed cholangitis. Acylcarnitine profile, urine succinylacetone, serum iron, and sweat chloride were normal. Serum amino acids and urine organic acids showed non-specific abnormalities. Of note, her serum A1AT level was low (47 mg/dL, ref 88-174), with a PiZZ phenotype.
In the weeks following the biopsy, she progressively decompensated. She had recurrent ascites while on diuretics, requiring 2 rounds of paracentesis. She was unable to maintain euglycemia without intravenous fluids or continuous feeds. She had marked coagulopathy (peak INR 5.7) that did not correct with fresh frozen plasma or vitamin K. Liver indices acutely worsened, requiring urgent listing for liver transplantation. There was a dramatic rise in her bilirubin (Supplemental Figure 1) , with total serum bilirubin 47.5 mg/dL and direct bilirubin 23.4 mg/dL just 4 weeks after biopsy. These elevations were highly unusual for A1ATD. Due to this severe cholestasis, other etiologies were re-considered; however, no specific causes were identified. At age 5 months, she underwent orthotopic liver transplantation from a 4-month old deceased donor 5 weeks after biopsy. Her liver function and hyperbilirubinemia rapidly improved after transplant (Supplemental Figure 1) . Post-operative course was complicated by parainfluenza virus requiring intubation, and a pericardial effusion which resolved. She was discharged home on post-operative day [POD] #35, and continues to do well 24 months post-transplant. She is the youngest patient we have transplanted for A1ATD at our center.
Pathology

Liver biopsy
The wedge biopsy showed marked nodularity of the liver parenchyma, with regenerative nodules separated by bands of fibrous tissue bridging portal areas (Figure 1(a) ). There was marked ductular proliferation within portal areas with abnormal forms, including some mimicking the lesions of ductal plate malformation, as seen on both the CK7 (Figure 1(b) ) and AE1/3 (Figure 1(c) ) cytokeratin stains. The AE1/3 stain showed an occasional wellpreserved interlobular bile duct. The exuberant bile ductular reaction made it difficult to differentiate the interlobular ducts from the ductular reaction in many portal areas. Overall, there appeared to be decreased numbers of interlobular bile ducts suggesting an element of paucity, though difficult to assess. There was some aberrant CK7 staining in hepatocytes. Bile ductular as well as canalicular plugs (Figure 1 
Liver Explant
The liver explant showed significant worsening and marked cholestasis, with canalicular and bile ductular plugs, bridging fibrosis, regenerative nodules, and cirrhosis ( Figure 1(h and (i) ). Prominent ballooning and intracellular cholestasis was noted. The trichrome stain highlighted bridging fibrosis and sinusoidal fibrosis. It showed marked ductular proliferation, better seen in the CK7 stain. The AE1/3 cytokeratin stain also showed ductular proliferation and portal areas with larger caliber interlobular ducts, though this was not evident in all portal areas. The degree of ductular proliferation made this distinction difficult in many areas. No ectopic hepatocyte staining was noted with CK7, a feature frequently seen with paucity of bile ducts. An A1AT stain showed diffuse staining of nodules with an accentuated staining in the periportal hepatocytes. Mixed micro-and macrovesicular steatosis was found in 80% of the liver parenchyma.
Discussion
Our case highlights several important lessons in the evaluation and progression of infantile cholestasis. Although this patient was initially well appearing, she did have subtle signs of feeding issues and poor weight gain, with intermittent skin and stool color changes prior to our evaluation at DOL 109. A heightened awareness for signs of possible cholestasis in the first 2 months of life is essential for both clinicians and families, especially to avoid delayed diagnosis of biliary atresia, since only 20% of infants achieve successful biliary drainage if Kasai is performed after DOL 90. 2 Successful anticipatory guidance for hypopigmented stools continues to be an area of quality improvement. [3] [4] [5] A precise cause of infantile hepatitis and cirrhosis is often difficult to define. The elevated GGT placed our patient in a category that includes biliary atresia, Alagille's syndrome, PFIC3, and possibly cystic fibrosis. This differential is usually resolved by a combination of clinical observation, imaging, determination of A1AT protein phenotype, liver biopsy, and/or genetic screening. The delay of a clear-cut diagnosis in this infant is partly the result of decisions made decades ago in the United States to abandon newborn screening for A1ATD because of low yield and sparse clinical effects in childhood. Of note, a recent workshop recommended a series of pilot studies focused on generating new data on the risks and benefits of newborn screening for A1ATD. 6 Our case exemplifies the diagnostic dilemmas often encountered when evaluating infantile cholestasis. This patient had signs of cholestasis and portal hypertension at a very young age, requiring inpatient admission to expedite her work-up. Since she deteriorated so rapidly after initial presentation, concurrent investigations led to some conflicting results. She had findings suspicious for biliary atresia and Alagille's syndrome, and while many screening labs were still pending, the liver biopsy performed at the time of intra-operative cholangiogram was essential in both diagnosing A1ATD and staging her disease, as well as ruling out other etiologies. Her initial liver histology was fairly impressive, since alpha-1 antitrypsin-Z (ATZ) protein globules may not be readily apparent in biopsies from PiZZ infants under the age of 3 months. 7 Our patient's subsequent clinical course is also quite unusual, since she progressed to decompensated cirrhosis in a month's time, with a rapid rise in her bilirubin atypical for A1ATD, and worsening fibrosis at time of liver transplant only 1 month later. Based on our single center experience, only 14 children have undergone orthotopic liver transplantation in the past 13 years, and the mean age at transplant was 4 years old. In a recent analysis of 3 US transplantation databases, 77.2% of 1677 total liver transplants with a reported diagnosis of A1ATD were adults (peak age 50-64), similar to other age-dependent degenerative disorders. 8 In contrast, children under age 5 are at highest risk only rarely, presumably due to powerful modifiers. 8 In the majority of cases diagnosed, infantile cholestasis gradually improves in A1ATD. 9, 10 Persistently elevated bilirubin has been shown to be a marker of poor prognosis. 11 A recent study reported that PiZZ infants with a mean deviation in total serum bilirubin of $5 mg/dL above the normal mean will have a poor outcome requiring liver transplantation. 11 Our patient was almost 10Â this deviation. As with any rapidly progressive organ failure, there exists the possibility of unidentified comorbidities, such as infection, medications, or multiple metabolic/genetic insults. Coexisting paucity in A1ATD could explain this severe degree of cholestasis to some extent, but could not be proven beyond a doubt on both the biopsy and the explant. There have been isolated reports of rapid deterioration and acute liver failure in infants with A1ATD and concomitant infections, such as congenital cytomegalovirus viremia, which was ruled out in our patient. 13, 14 Since she required early liver transplantation, we were unable to send whole-exome sequencing, which may have revealed a ''second hit.'' Nevertheless, her post-transplant course has thus far been reassuring and does not suggest coexisting systemic disease.
A1ATD is the most common inherited pediatric liver disorder and the most frequent genetic cause of liver transplantation in children (reviewed in Ghouse et al. 14, 15 ). In its classical form, A1ATD is an autosomal co-dominant disorder that affects as many as 1 in 3000 live births in the United States and Europe. The genetic defect in A1ATD involves homozygosity for the Z allele (PiZZ) in the SERPINA1 gene on human chromosome 14, encoding a single base pair substitution leading to Glu342Lys. The resulting toxic gain-of-function mutation generates misfolded ATZ protein that accumulates in the ER of hepatocytes, forming insoluble globules that are PASþ/diastaseresistant. Chronic hepatocyte injury can progress over time to cirrhosis and hepatocellular carcinoma in some individuals. Liver transplantation remains the only treatment for patients with severe liver disease; however, it is often not required in childhood. In fact, prospective studies of a Swedish cohort of PiZZ newborns reported that only $8% of homozygotes develop clinically significant liver disease in the first 4 decades of life. 16, 17 This suggests the role of other genetic and/or environmental modifiers of disease susceptibility; however, it is difficult to predict which factors predispose some patients to develop liver disease while sparing others. Interestingly, severe neonatal A1ATD may be associated with infants having low birth weight or poor weight gain. 8, 17 In summary, manifestations and prognosis of A1ATD are highly variable. Our patient represents an unusual case of aggressive A1ATD-related liver disease leading to end-stage cirrhosis in the first 4 months of life, and this suggests very early onset of chronic hepatocellular injury, possibly during neonatal or even fetal development.
